Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol

Leanne Hodson; Sion A. Parry; Thomas Cornfield; Catriona Charlton; Wee Suan Low; Charlotte J. Green; Fredrik Rosqvist

doi:10.1080/03009734.2020.1739789

Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol

Leanne Hodson, Sion A. Parry, Thomas Cornfield, Catriona Charlton, Wee Suan Low, Charlotte J. Green, Fredrik Rosqvist^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Background: Hepatic de novo lipogenesis (DNL) is ideally measured in very low-density lipoprotein (VLDL)-triacylglycerol (TAG). In the fasting state, the majority of plasma TAG typically represents VLDL-TAG; however, the merits of measuring DNL in total plasma TAG have not been assessed. This study aimed to assess the performance of DNL measured in VLDL-TAG (DNL_VLDL-TAG) compared to that measured in total plasma TAG (DNL_Plasma-TAG). Methods: Using deuterated water, newly synthesised palmitate was determined in fasting plasma VLDL-TAG and total TAG in 63 subjects taking part in multiple studies resulting in n = 123 assessments of DNL (%new palmitate of total palmitate). Subjects were split into tertiles to investigate if DNL_Plasma-TAG could correctly classify subjects having ‘high’ (top tertile) and ‘low’ (bottom tertile) DNL. Repeatability was assessed in a subgroup (n = 16) with repeat visits. Results: DNL_VLDL-TAG was 6.8% (IQR 3.6–10.7%) and DNL_Plasma-TAG was 7.5% (IQR 4.0%−11.0%), and the correlation between the methods was r_s = 0.62 (p < 0.0001). Bland–Altman plots demonstrated similar performance (mean difference 0.81%, p = 0.09); however, the agreement interval was wide (−9.6% to 11.2%). Compared to DNL_VLDL-TAG, 54% of subjects with low DNL were correctly classified, whilst 66% of subjects with high DNL were correctly classified using DNL_Plasma-TAG. Repeatability was acceptable (i.e. not different) at the group level, but the majority of subjects had an intra-individual variability over 25%. Conclusion: DNL in total plasma TAG performed similarly to DNL in VLDL-TAG at the group level, but there was large variability at the individual level. We suggest that plasma TAG could be useful for comparing DNL between groups.

Original language	English
Pages (from-to)	211-216
Number of pages	6
Journal	Upsala Journal of Medical Sciences
Volume	125
Issue number	3
Early online date	25 Mar 2020
DOIs	https://doi.org/10.1080/03009734.2020.1739789
Publication status	Published - 2 Jul 2020

Funding

FR is supported by Henning and Johan Throne-Holsts Foundation, Swedish Society for Medical Research, Swedish Society of Medicine, and The Foundation Blanceflor. LH is a British Heart Foundation Senior Research Fellow in Basic Science (FS/15/56/31645). Authors thank Louise Dennis, Rachel Craven-Todd, and CRU staff for excellent nursing provision, and Niall Dempster and Jonathan Hazlehurst for medical cover. This work was supported by the NIHR Biomedical Research Centre, Oxford, and Authors thank the volunteers from the Oxford Biobank, NIHR Oxford Biomedical Research Centre, for their participation. The Oxford Biobank (www.oxfordbiobank.org.uk) is also part of the NIHR National Bioresource which supported the recalling process of the volunteers. A small number of samples analysed in this paper were from CJG?s Novo Nordisk postdoctoral fellowship run in partnership with the University of Oxford.

Keywords

De novo lipogenesis
DNL
hepatic
human
triacylglycerol
VLDL

Access to Document

10.1080/03009734.2020.1739789

Cite this

@article{277e4b5f5c5e4c8e8ac46752ffa848b8,

title = "Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol",

abstract = "Background: Hepatic de novo lipogenesis (DNL) is ideally measured in very low-density lipoprotein (VLDL)-triacylglycerol (TAG). In the fasting state, the majority of plasma TAG typically represents VLDL-TAG; however, the merits of measuring DNL in total plasma TAG have not been assessed. This study aimed to assess the performance of DNL measured in VLDL-TAG (DNLVLDL-TAG) compared to that measured in total plasma TAG (DNLPlasma-TAG). Methods: Using deuterated water, newly synthesised palmitate was determined in fasting plasma VLDL-TAG and total TAG in 63 subjects taking part in multiple studies resulting in n = 123 assessments of DNL (%new palmitate of total palmitate). Subjects were split into tertiles to investigate if DNLPlasma-TAG could correctly classify subjects having {\textquoteleft}high{\textquoteright} (top tertile) and {\textquoteleft}low{\textquoteright} (bottom tertile) DNL. Repeatability was assessed in a subgroup (n = 16) with repeat visits. Results: DNLVLDL-TAG was 6.8% (IQR 3.6–10.7%) and DNLPlasma-TAG was 7.5% (IQR 4.0%−11.0%), and the correlation between the methods was rs = 0.62 (p < 0.0001). Bland–Altman plots demonstrated similar performance (mean difference 0.81%, p = 0.09); however, the agreement interval was wide (−9.6% to 11.2%). Compared to DNLVLDL-TAG, 54% of subjects with low DNL were correctly classified, whilst 66% of subjects with high DNL were correctly classified using DNLPlasma-TAG. Repeatability was acceptable (i.e. not different) at the group level, but the majority of subjects had an intra-individual variability over 25%. Conclusion: DNL in total plasma TAG performed similarly to DNL in VLDL-TAG at the group level, but there was large variability at the individual level. We suggest that plasma TAG could be useful for comparing DNL between groups.",

keywords = "De novo lipogenesis, DNL, hepatic, human, triacylglycerol, VLDL",

author = "Leanne Hodson and Parry, {Sion A.} and Thomas Cornfield and Catriona Charlton and Low, {Wee Suan} and Green, {Charlotte J.} and Fredrik Rosqvist",

year = "2020",

month = jul,

day = "2",

doi = "10.1080/03009734.2020.1739789",

language = "English",

volume = "125",

pages = "211--216",

journal = "Upsala Journal of Medical Sciences",

issn = "0300-9734",

publisher = "Upsala Medical Society",

number = "3",

}

TY - JOUR

T1 - Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol

AU - Hodson, Leanne

AU - Parry, Sion A.

AU - Cornfield, Thomas

AU - Charlton, Catriona

AU - Low, Wee Suan

AU - Green, Charlotte J.

AU - Rosqvist, Fredrik

PY - 2020/7/2

Y1 - 2020/7/2

N2 - Background: Hepatic de novo lipogenesis (DNL) is ideally measured in very low-density lipoprotein (VLDL)-triacylglycerol (TAG). In the fasting state, the majority of plasma TAG typically represents VLDL-TAG; however, the merits of measuring DNL in total plasma TAG have not been assessed. This study aimed to assess the performance of DNL measured in VLDL-TAG (DNLVLDL-TAG) compared to that measured in total plasma TAG (DNLPlasma-TAG). Methods: Using deuterated water, newly synthesised palmitate was determined in fasting plasma VLDL-TAG and total TAG in 63 subjects taking part in multiple studies resulting in n = 123 assessments of DNL (%new palmitate of total palmitate). Subjects were split into tertiles to investigate if DNLPlasma-TAG could correctly classify subjects having ‘high’ (top tertile) and ‘low’ (bottom tertile) DNL. Repeatability was assessed in a subgroup (n = 16) with repeat visits. Results: DNLVLDL-TAG was 6.8% (IQR 3.6–10.7%) and DNLPlasma-TAG was 7.5% (IQR 4.0%−11.0%), and the correlation between the methods was rs = 0.62 (p < 0.0001). Bland–Altman plots demonstrated similar performance (mean difference 0.81%, p = 0.09); however, the agreement interval was wide (−9.6% to 11.2%). Compared to DNLVLDL-TAG, 54% of subjects with low DNL were correctly classified, whilst 66% of subjects with high DNL were correctly classified using DNLPlasma-TAG. Repeatability was acceptable (i.e. not different) at the group level, but the majority of subjects had an intra-individual variability over 25%. Conclusion: DNL in total plasma TAG performed similarly to DNL in VLDL-TAG at the group level, but there was large variability at the individual level. We suggest that plasma TAG could be useful for comparing DNL between groups.

AB - Background: Hepatic de novo lipogenesis (DNL) is ideally measured in very low-density lipoprotein (VLDL)-triacylglycerol (TAG). In the fasting state, the majority of plasma TAG typically represents VLDL-TAG; however, the merits of measuring DNL in total plasma TAG have not been assessed. This study aimed to assess the performance of DNL measured in VLDL-TAG (DNLVLDL-TAG) compared to that measured in total plasma TAG (DNLPlasma-TAG). Methods: Using deuterated water, newly synthesised palmitate was determined in fasting plasma VLDL-TAG and total TAG in 63 subjects taking part in multiple studies resulting in n = 123 assessments of DNL (%new palmitate of total palmitate). Subjects were split into tertiles to investigate if DNLPlasma-TAG could correctly classify subjects having ‘high’ (top tertile) and ‘low’ (bottom tertile) DNL. Repeatability was assessed in a subgroup (n = 16) with repeat visits. Results: DNLVLDL-TAG was 6.8% (IQR 3.6–10.7%) and DNLPlasma-TAG was 7.5% (IQR 4.0%−11.0%), and the correlation between the methods was rs = 0.62 (p < 0.0001). Bland–Altman plots demonstrated similar performance (mean difference 0.81%, p = 0.09); however, the agreement interval was wide (−9.6% to 11.2%). Compared to DNLVLDL-TAG, 54% of subjects with low DNL were correctly classified, whilst 66% of subjects with high DNL were correctly classified using DNLPlasma-TAG. Repeatability was acceptable (i.e. not different) at the group level, but the majority of subjects had an intra-individual variability over 25%. Conclusion: DNL in total plasma TAG performed similarly to DNL in VLDL-TAG at the group level, but there was large variability at the individual level. We suggest that plasma TAG could be useful for comparing DNL between groups.

KW - De novo lipogenesis

KW - DNL

KW - hepatic

KW - human

KW - triacylglycerol

KW - VLDL

UR - http://www.scopus.com/inward/record.url?scp=85082482158&partnerID=8YFLogxK

UR - https://ujms.net/index.php/ujms/article/view/5604

U2 - 10.1080/03009734.2020.1739789

DO - 10.1080/03009734.2020.1739789

M3 - Article

C2 - 32208800

AN - SCOPUS:85082482158

SN - 0300-9734

VL - 125

SP - 211

EP - 216

JO - Upsala Journal of Medical Sciences

JF - Upsala Journal of Medical Sciences

IS - 3

ER -

Using total plasma triacylglycerol to assess hepatic de novo lipogenesis as an alternative to VLDL triacylglycerol

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this